Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Autoimmune Disorders

  Free Subscription

Articles published in Ann Neurol

Retrieve available abstracts of 127 articles:
HTML format

Single Articles

    April 2021
  1. MIRO O, Porta-Etessam J, Gonzalez Del Castillo J
    Reply to: "COVID-19 and the Risk of GBS".
    Ann Neurol. 2021;89:846-847.

    March 2021
  2. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    PubMed     Abstract available

  3. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    PubMed     Abstract available

    February 2021
  4. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    PubMed     Abstract available

  5. DUBEY D, Kryzer T, Guo Y, Clarkson B, et al
    LUZP4 autoantibody: A novel germ cell tumor and paraneoplastic biomarker.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26050.
    PubMed     Abstract available

    January 2021
  6. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    PubMed     Abstract available

  7. KOAY S, Vichayanrat E, Bremner F, Panicker JN, et al
    Multi-modal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.
    Ann Neurol. 2021 Jan 13. doi: 10.1002/ana.26018.
    PubMed     Abstract available

  8. LEE ST, Lee BJ, Bae JY, Kim YS, et al
    CaV alpha2delta Autoimmune Encephalitis: A Novel Antibody and its Characteristics.
    Ann Neurol. 2021 Jan 7. doi: 10.1002/ana.26017.
    PubMed     Abstract available

    Coronavirus Disease 2019 and the Risk of Guillain-Barre Syndrome.
    Ann Neurol. 2021 Jan 4. doi: 10.1002/ana.26011.

    December 2020
  10. FRAGIEL M, Miro O, Llorens P, Jimenez S, et al
    Incidence, clinical characteristics, risk factors and outcomes of Guillain-Barre syndrome in patients with Covid-19.
    Ann Neurol. 2020 Dec 9. doi: 10.1002/ana.25987.
    PubMed     Abstract available

    November 2020
  11. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    PubMed     Abstract available

  12. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    PubMed     Abstract available

    October 2020
  13. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.

  14. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.

  15. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    PubMed     Abstract available

    September 2020
  16. VARLEY JA, Andersson M, Grant E, Berretta A, et al
    Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25908.
    PubMed     Abstract available

  17. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.

  18. CARCELES-CORDON M, Mannara F, Aguilar E, Castellanos A, et al
    NMDAR Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice.
    Ann Neurol. 2020;88:603-613.
    PubMed     Abstract available

    August 2020
  19. PALMA JA, Gupta A, Sierra S, Gomes I, et al
    Autoantibodies blocking M3 muscarinic receptors cause postganglionic cholinergic dysautonomia.
    Ann Neurol. 2020 Aug 24. doi: 10.1002/ana.25882.
    PubMed     Abstract available

  20. MAGGI P, Sati P, Nair G, Cortese ICM, et al
    Ann Neurol. 2020 Aug 15. doi: 10.1002/ana.25877.
    PubMed     Abstract available

  21. LANDA J, Gaig C, Planaguma J, Saiz A, et al
    Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration.
    Ann Neurol. 2020 Aug 2. doi: 10.1002/ana.25857.
    PubMed     Abstract available

  22. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    PubMed     Abstract available

    July 2020
    Progressive Multiple Sclerosis.
    Ann Neurol. 2020 Jul 6. doi: 10.1002/ana.25802.

  24. KORALNIK IJ, Tyler KL
    COVID-19: A Global Threat to the Nervous System.
    Ann Neurol. 2020;88:1-11.
    PubMed     Abstract available

  25. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    PubMed     Abstract available

    June 2020
  26. PETROVA N, Nutma E, Carassiti D, Newman J, et al
    Synaptic loss in the multiple sclerosis spinal cord.
    Ann Neurol. 2020 Jun 30. doi: 10.1002/ana.25835.
    PubMed     Abstract available

  27. RAUSCHENBERGER V, Wardenburg NV, Schaefer N, Ogino K, et al
    GlyR autoantibodies impair receptor function and induce motor dysfunction.
    Ann Neurol. 2020 Jun 26. doi: 10.1002/ana.25832.
    PubMed     Abstract available

  28. FILIPPI M, Preziosa P, Langdon D, Lassmann H, et al
    Identifying Progression In Multiple Sclerosis: New Perspectives.
    Ann Neurol. 2020 Jun 7. doi: 10.1002/ana.25808.
    PubMed     Abstract available

  29. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    PubMed     Abstract available

    May 2020
  30. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    PubMed     Abstract available

  31. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    PubMed     Abstract available

  32. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.

  33. LEE ST, Lim JA, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: When to evaluate?"
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25760.

  34. CAI MT, Zheng Y, Zhang YX
    Grading the severity of autoimmune encephalitis: When to evaluate?
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25761.

    April 2020
  35. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.

  36. BARTELS F, Krohn S, Nikolaus M, Johannsen J, et al
    Clinical and MRI Outcome Predictors in Pediatric Anti-NMDA Receptor Encephalitis.
    Ann Neurol. 2020 Apr 21. doi: 10.1002/ana.25754.
    PubMed     Abstract available

  37. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    PubMed     Abstract available

  38. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    PubMed     Abstract available

  39. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    PubMed     Abstract available

  40. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    PubMed     Abstract available

    March 2020
  41. PITSCH J, Kamalizade D, Braun A, Kuehn JC, et al
    Drebrin autoantibodies in patients with seizures and suspected encephalitis.
    Ann Neurol. 2020 Mar 20. doi: 10.1002/ana.25720.
    PubMed     Abstract available

  42. DE MOL CL, Jansen PR, Muetzel RL, Knol MJ, et al
    Polygenic multiple sclerosis risk and population-based childhood brain imaging.
    Ann Neurol. 2020 Mar 12. doi: 10.1002/ana.25717.
    PubMed     Abstract available

  43. RICHIE M, Pleasure S, Hurley J, Goss A, et al
    ANA Investigates: Pioneering Unbiased Diagnostics.
    Ann Neurol. 2020;87:327-328.

    February 2020
  44. OUELLETTE R, Mangeat G, Polyak I, Warntjes M, et al
    Validation of rapid magnetic resonance myelin imaging in multiple sclerosis.
    Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705.
    PubMed     Abstract available

  45. ALPING P, Askling J, Burman J, Fink K, et al
    Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.
    Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701.
    PubMed     Abstract available

  46. MATUTE C, Palma A, Serrano-Regal MP, Maudes E, et al
    NMDA receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function.
    Ann Neurol. 2020 Feb 12. doi: 10.1002/ana.25699.
    PubMed     Abstract available

  47. DALMAU J
    Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases.
    Ann Neurol. 2020;87:324-325.

  48. JUREK B, Chayka M, Kreye J, Koelch M, et al
    Reply to "Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases".
    Ann Neurol. 2020;87:325-326.

    January 2020
  49. OLDONI E, Smets I, Mallants K, Vandebergh M, et al
    CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity.
    Ann Neurol. 2020 Jan 29. doi: 10.1002/ana.25691.
    PubMed     Abstract available

  50. DOBSON R, Jitlal M, Marshall CR, Noyce AJ, et al
    Ethnic and socioeconomic associations with multiple sclerosis risk.
    Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688.
    PubMed     Abstract available

  51. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    PubMed     Abstract available

  52. KORNAU HC, Kreye J, Stumpf A, Fukata Y, et al
    Human CSF monoclonal LGI1 autoantibodies increase neuronal excitability.
    Ann Neurol. 2020 Jan 3. doi: 10.1002/ana.25666.
    PubMed     Abstract available

    November 2019
  53. DUBEY D, Britton J, McKeon A, Gadoth A, et al
    Randomized Placebo Controlled Trial of IVIG in autoimmune LGI1/CASPR2 epilepsy.
    Ann Neurol. 2019 Nov 28. doi: 10.1002/ana.25655.
    PubMed     Abstract available

  54. CHUNG KK, Altmann D, Barkhof F, Miszkiel K, et al
    A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes.
    Ann Neurol. 2019 Nov 6. doi: 10.1002/ana.25637.
    PubMed     Abstract available

  55. PROBSTEL AK, Zamvil SS
    Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?
    Ann Neurol. 2019;86:653-655.

    September 2019
  56. KRYSKO KM, Henry RG, Cree BAC, Lin J, et al
    Telomere length is associated with disability progression in multiple sclerosis.
    Ann Neurol. 2019 Sep 4. doi: 10.1002/ana.25592.
    PubMed     Abstract available

    August 2019
  57. MOCCIA M, Prados F, Filippi M, Rocca MA, et al
    Longitudinal spinal cord atrophy in multiple sclerosis using the generalised boundary shift integral.
    Ann Neurol. 2019 Aug 6. doi: 10.1002/ana.25571.
    PubMed     Abstract available

  58. LOONSTRA FC, Verberk IMW, Wijburg MT, Wattjes MP, et al
    Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Ann Neurol. 2019;86:322-324.

  59. DALLA COSTA G, Martinelli V, Furlan R, Comi G, et al
    Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Ann Neurol. 2019;86:324.

    July 2019
  60. JUREK B, Chayka M, Kreye J, Lang K, et al
    Human gestational NMDAR autoantibodies impair neonatal murine brain function.
    Ann Neurol. 2019 Jul 20. doi: 10.1002/ana.25552.
    PubMed     Abstract available

    June 2019
  61. GIL-PEROTIN S, Alcala C, Perez-Miralles FC, Casanova B, et al
    Silent progression or bout-onset progressive multiple sclerosis?
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25537.

  62. CREE BAC, Hauser SL
    Reply to "Silent progression or bout-onset progressive multiple sclerosis?"
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25536.

  63. MUNGER KL, Hongell K, Cortese M, Aivo J, et al
    Epstein-Barr virus and multiple sclerosis risk in the Finnish Maternity Cohort.
    Ann Neurol. 2019 Jun 21. doi: 10.1002/ana.25532.
    PubMed     Abstract available

    May 2019
  64. VAN LANGELAAR J, Rijvers L, Janssen M, Wierenga-Wolf AF, et al
    Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.
    Ann Neurol. 2019 May 28. doi: 10.1002/ana.25508.
    PubMed     Abstract available

  65. LIM JA, Lee ST, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: advances and pitfalls".
    Ann Neurol. 2019 May 2. doi: 10.1002/ana.25497.

  66. SPAGNI G, Iorio R
    Grading the severity of autoimmune encephalitis: advances and pitfalls.
    Ann Neurol. 2019 May 2. doi: 10.1002/ana.25496.

  67. NOLAN-KENNEY RC, Liu M, Akhand O, Calabresi PA, et al
    Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
    Ann Neurol. 2019;85:618-629.
    PubMed     Abstract available

  68. WENKE NK, Kreye J, Andrzejak E, van Casteren A, et al
    N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit.
    Ann Neurol. 2019;85:771-776.
    PubMed     Abstract available

    March 2019
  69. AKTAS O, Hartung HP
    CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.
    Ann Neurol. 2019 Mar 22. doi: 10.1002/ana.25471.

  70. CREE BAC, Hollenbach JA, Bove R, Kirkish G, et al
    Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis.
    Ann Neurol. 2019 Mar 9. doi: 10.1002/ana.25463.
    PubMed     Abstract available

  71. THALER FS, Thaller AL, Biljecki M, Schuh E, et al
    Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.
    Ann Neurol. 2019;85:448-454.
    PubMed     Abstract available

    February 2019
  72. DALLA COSTA G, Martinelli V, Moiola L, Sangalli F, et al
    Serum neurofilaments increase at PML onset in natalizumab-treated MS patients.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25437.
    PubMed     Abstract available

  73. FADDA G, Brown RA, Magliozzi R, Aubert-Broche B, et al
    A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.
    Ann Neurol. 2019 Feb 4. doi: 10.1002/ana.25429.
    PubMed     Abstract available

    January 2019
  74. LIM JA, Lee ST, Moon J, Jun JS, et al
    Development of the Clinical Assessment Scale in Autoimmune Encephalitis (CASE).
    Ann Neurol. 2019 Jan 24. doi: 10.1002/ana.25421.
    PubMed     Abstract available

  75. BAERT L, Benkhoucha M, Popa N, Ahmed MC, et al
    APRIL-mediated anti-inflammatory response of astrocytes in multiple sclerosis.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25415.
    PubMed     Abstract available

  76. CACCIAGUERRA L, Meani A, Mesaros S, Radaelli M, et al
    Brain and cord imaging features in neuromyelitis optica spectrum disorders.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411.
    PubMed     Abstract available

    October 2018
  77. BEVAN RJ, Evans R, Griffiths L, Watkins LM, et al
    Ann Neurol. 2018 Oct 25. doi: 10.1002/ana.25365.
    PubMed     Abstract available

    September 2018
  78. HE D, Zhang H, Xiao J, Zhang X, et al
    Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis.
    Ann Neurol. 2018;84:386-400.
    PubMed     Abstract available

    August 2018
  79. WOLINSKY JS, Montalban X, Hauser SL, Giovannoni G, et al
    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Ann Neurol. 2018 Aug 29. doi: 10.1002/ana.25313.
    PubMed     Abstract available

  80. SEBASTIAN LOPEZ-CHIRIBOGA A, Klein C, Zekeridou A, McKeon A, et al
    LGI1 and CASPR2 Neurological Autoimmunity in Children.
    Ann Neurol. 2018 Aug 3. doi: 10.1002/ana.25310.
    PubMed     Abstract available

    July 2018
  81. FUJII T, Yamasaki R, Iinuma K, Tsuchimoto D, et al
    A novel autoantibody against plexin D1 in patients with neuropathic pain.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25279.
    PubMed     Abstract available

    June 2018
  82. JIA X, Madireddy L, Caillier S, Santaniello A, et al
    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
    Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25263.
    PubMed     Abstract available

    May 2018
  83. DISANTO G, Zecca C, MacLachlan S, Sacco R, et al
    Prodromal symptoms of multiple sclerosis in primary care.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25247.
    PubMed     Abstract available

    April 2018
  84. TANKOU SK, Regev K, Healy BC, Tjon E, et al
    A probiotic modulates the microbiome and immunity in multiple sclerosis.
    Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
    PubMed     Abstract available

  85. VOGRIG A, Brigo F, Valente M, Gigli GL, et al
    Epidemiology of autoimmune versus infectious encephalitis.
    Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25229.

  86. DUBEY D, Pittock SJ, Toledano M, Flanagan EP, et al
    Reply to "Epidemiology of autoimmune versus infectious encephalitis".
    Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25230.

    March 2018
  87. CRAMER SP, Simonsen HJ, Varatharaj A, Galea I, et al
    Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
    Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25219.
    PubMed     Abstract available

  88. ANTEL J
    The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.

  89. COLES A
    Authorship of phase 3 trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25203.

  90. MAGLIOZZI R, Howell OW, Nicholas R, Cruciani C, et al
    Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25197.
    PubMed     Abstract available

    February 2018
  91. JENDE JME, Groener JB, Oikonomou D, Heiland S, et al
    Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography.
    Ann Neurol. 2018 Feb 14. doi: 10.1002/ana.25182.
    PubMed     Abstract available

  92. BECK ES, Reich DS
    Brain atrophy in multiple sclerosis: How deep must we go?
    Ann Neurol. 2018;83:208-209.

  93. MAGGI P, Absinta M, Grammatico M, Vuolo L, et al
    Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.
    Ann Neurol. 2018;83:283-294.
    PubMed     Abstract available

    January 2018
  94. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
    Deep grey matter volume loss drives disability worsening in multiple sclerosis.
    Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
    PubMed     Abstract available

  95. AZEVEDO CJ, Cen SY, Khadka S, Liu S, et al
    Thalamic Atrophy in MS: An MRI Marker of Neurodegeneration Throughout Disease.
    Ann Neurol. 2018 Jan 12. doi: 10.1002/ana.25150.
    PubMed     Abstract available

  96. DUBEY D, Pittock SJ, Kelly CR, McKeon A, et al
    Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis.
    Ann Neurol. 2018 Jan 2. doi: 10.1002/ana.25131.
    PubMed     Abstract available

    December 2017
  97. GILES DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, et al
    Myeloid cell plasticity in the evolution of central nervous system autoimmunity.
    Ann Neurol. 2017 Dec 28. doi: 10.1002/ana.25128.
    PubMed     Abstract available

  98. GREENFIELD AL, Hauser SL
    B Cell Therapy for Multiple Sclerosis: Entering an Era.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25119.
    PubMed     Abstract available

  99. PATTERSON KR, Dalmau J, Lancaster E
    Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25120.
    PubMed     Abstract available

    November 2017
  100. KANAI T, Uzawa A, Sato Y, Suzuki S, et al
    A clinical predictive score for postoperative myasthenic crisis.
    Ann Neurol. 2017;82:841-849.
    PubMed     Abstract available

    October 2017
  101. BARBOUR C, Kosa P, Komori M, Tanigawa M, et al
    Molecular-based diagnosis of Multiple Sclerosis and its progressive stage.
    Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25083.
    PubMed     Abstract available

  102. AZODI S, Nair G, Enose-Akahata Y, Charlip E, et al
    Imaging Spinal Cord Atrophy in Progressive Myelopathies: HTLV-I Associated Neurologic Disease (HAM/TSP) and Multiple Sclerosis (MS).
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25072.
    PubMed     Abstract available

  103. JENDE JME, Hauck GH, Diem R, Weiler M, et al
    Peripheral nerve involvement in multiple sclerosis Demonstration by magnetic resonance neurography.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25068.
    PubMed     Abstract available

  104. MAINERO C, Louapre C
    Unravelling cortical pathology in multiple sclerosis using the T1-/T2-weighted ratio?
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25063.

  105. WIJNANDS JMA, Tremlett H
    Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25061.

  106. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Reply to: Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25062.

    September 2017
  107. FITZGERALD KC, Munger KL, Ascherio A
    Reply to "Stratified analyses are necessary to verify the influence of salt intake in multiple sclerosis".
    Ann Neurol. 2017 Sep 29. doi: 10.1002/ana.25055.

  108. ZAHEDNASAB H, Harirchian MH, Karampoor S, Keyvani H, et al
    MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25037.

  109. FISSOLO N, Pignolet B, Brassat D, Comabella M, et al
    Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25039.

  110. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Concussion in adolescence and risk of multiple sclerosis.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25036.
    PubMed     Abstract available

    August 2017
  111. NAKAMURA K, Chen JT, Ontaneda D, Fox RJ, et al
    T1-/T2-weighted ratio differs in demyelinated cortex of multiple sclerosis.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25019.
    PubMed     Abstract available

  112. RIGHART R, Biberacher V, Jonkman LE, Klaver R, et al
    Cortical pathology in MS detected by the T1/T2-weighted ratio from routine MRI.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25020.
    PubMed     Abstract available

  113. DALAKAS MC, Rakocevic G, Dambrosia JM, Alexopoulos H, et al
    A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.
    Ann Neurol. 2017;82:271-277.
    PubMed     Abstract available

    July 2017
  114. YATES RL, Esiri MM, Palace J, Jacobs B, et al
    Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
    Ann Neurol. 2017 Jul 18. doi: 10.1002/ana.24997.
    PubMed     Abstract available

  115. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
    MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
    Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
    PubMed     Abstract available

    May 2017
  116. FITZGERALD KC, Munger KL, Hartung HP, Freedman MS, et al
    Sodium intake and multiple sclerosis activity and progression in BENEFIT.
    Ann Neurol. 2017 May 26. doi: 10.1002/ana.24965.
    PubMed     Abstract available

  117. DISANTO G, Barro C, Benkert P, Naegelin Y, et al
    Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Ann Neurol. 2017 May 16. doi: 10.1002/ana.24954.
    PubMed     Abstract available

  118. CUI QL, Khan D, Rone M, Rao V, et al
    Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
    Ann Neurol. 2017 May 3. doi: 10.1002/ana.24944.
    PubMed     Abstract available

  119. IAFFALDANO P, Simone M, Lucisano G, Ghezzi A, et al
    Prognostic indicators in pediatric clinically isolated syndrome.
    Ann Neurol. 2017;81:729-739.
    PubMed     Abstract available

    April 2017
  120. ANDRODIAS G, Bernard E, Biotti D, Collongues N, et al
    Multiple sclerosis broke my heart.
    Ann Neurol. 2017 Apr 24. doi: 10.1002/ana.24935.
    PubMed     Abstract available

  121. SELMAJ I, Cichalewska M, Namiecinska M, Galazka G, et al
    Global Exosome Transcriptome Profiling Reveals Biomarkers for Multiple Sclerosis.
    Ann Neurol. 2017 Apr 15. doi: 10.1002/ana.24931.
    PubMed     Abstract available

    March 2017
  122. TAWARA N, Yamashita S, Zhang X, Korogi M, et al
    Pathomechanisms of anti-cN1A autoantibodies in sporadic inclusion body myositis.
    Ann Neurol. 2017 Mar 20. doi: 10.1002/ana.24919.
    PubMed     Abstract available

  123. TREMLETT H, Bauer KC, Appel-Cresswell S, Finlay BB, et al
    The gut microbiome in human neurological disease: A review.
    Ann Neurol. 2017;81:369-382.
    PubMed     Abstract available

    February 2017
  124. KIM TJ, Lee ST, Moon J, Sunwoo JS, et al
    Anti-LGI1 encephalitis is associated with unique HLA subtypes.
    Ann Neurol. 2017;81:183-192.
    PubMed     Abstract available

    December 2016
  125. HERRANZ E, Hooker JM, Izquierdo-Garcia D, Loggia ML, et al
    11 C-PBR28 increase in multiple sclerosis reflects neuroinflammation.
    Ann Neurol. 2016 Dec 29. doi: 10.1002/ana.24865.

  126. RAFFEL J, Sridharan S, Nicholas R
    [11 C]PBR-28 PET in multiple sclerosis: Neuroinflammation or otherwise?
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24853.

    July 2016
  127. WHITE MK, Wollebo HS, Beckham JD, Tyler KL, et al
    Zika virus: An emergent neuropathological agent.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24748.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.